Gilead Sciences, Inc.
- SEC CIK
- 0000882095
- Latest filing
- Aug 3, 2026
Holdings in Q1 2026
Holdings as of Mar 31, 2026, filed May 8, 2026. Long positions only; changes compare share counts with Q4 2025.
- Positions
- 6
- 0 vs. Q4 2025
- Portfolio value
- $2.12B
- +$182.3M (+9.4%) vs. Q4 2025
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| ACLXArcellx, Inc. | COMMON STOCK | 6,720,803 | $771.7M | 36.4% | 00.0% | Unchanged | History |
| RCUSArcus Biosciences, Inc. | COM | 31,424,760 | $678.8M | 32.1% | 00.0% | Unchanged | History |
| LKFTLakefront Biotherapeutics NV | SPON ADR | 16,707,477 | $501.2M | 23.7% | 00.0% | Unchanged | History |
| ASMBAssembly Biosciences, Inc. | COM NEW | 4,505,391 | $125.0M | 5.9% | 00.0% | Unchanged | History |
| KYTXKyverna Therapeutics, Inc. | COM | 4,126,119 | $35.6M | 1.7% | 00.0% | Unchanged | History |
| XLOXilio Therapeutics, Inc. | COM | 650,389 | $5.47M | 0.3% | 00.0% | UnchangedConverted for a 1-for-14 split | History |